The Genomic Revolution: Top 10 Companies at the Forefront of Pharmacogenomics

The Pharmacogenomics Market is projected to reach $19.5 billion by 2031, at a CAGR of 8.9% during the forecast period 2024–2031. The pharmacogenomics market includes consumables, instruments, and software & services. The pharmacogenomics market is driven by the growing therapeutic applications of pharmacogenomic biomarkers, the increasing adoption of personalized medicines, the rising geriatric population and chronic disease prevalence, and the U.S. FDA’s and EMA’s recommendations for using pharmacogenomic data in drug discovery & development.